Surgical Site Infection Prevention:

Prof. Erez Kachel

Head of Cardiothoracic Surgery in Poria Medical Center, Israel, Deputy director of the Department of cardiac surgery at the Sheba Medical Center, and the Chief Manager of the Wounds Clinic for Post-cardiac Surgery and the CEO, medical director and senior surgeon in the Cardioheal group. He is also a supervisor of students and lecturer of several courses at the Tel Aviv University. Dr. Kachel is responsible for changing the therapeutic approach to thoracic infection treatment for patients both here and abroad, by providing significantly improved survival rates and better quality of life for these patients. He has published many articles on this subject in international medical journals. Dr. Kachel did his clinical fellowship in the cardiovascular department at the SunnyBrook M edical Center in Toronto Canada between the tears 2009-20011, did his cardiothoracic surgery residency at the Sheba Medical Center and graduated Medical School at the Ben Gurion University of the Negev.

Prof. Hartzell V. Schaff

Dr. Schaff is the Stuart W. Harrington Professor of Surgery and a consultant in the Division of Cardiovascular Surgery at Mayo Clinic, Rochester, Minnesota. He is a member of major international societies, including the American Association for Thoracic Surgery (2012-2013 President). He has authored or co-authored 784 papers, 94 book chapters, edited or written 9 textbooks and delivered over 500 lectures. He has served or is serving on the editorial boards of 11 journals including Circulation and the Journal of Thoracic and Cardiovascular Surgery, where he is currently the Associate Editor. Dr. Schaff received his medical degree and training at the University Of Oklahoma School Of Medicine where he also completed an NIH Research Fellowship. His surgical training was completed at Johns Hopkins Hospital.

Prof. Moshe Salai

Head of the orthopedic division of the Tel-Aviv Sourasky Medical Center (Ichilov), a Level-1 trauma center, affiliated with the Sackler Faculty of Medicine, Tel-Aviv University. Prof. Salai, completed his training at the, Sheba Medical Center, Israel, then served as the head of orthopedic department at the Beilinson Hospital, Rabin Medical Center, Israel and in his current position since 2010. Prof. Salai has extensive clinical and scientific experience, with over 120 PubMed cited publications. He is the head of the Israel Association of Tissue Banking, and the Israel Medical Association Council, and formerly was the president of the EATB (European Association of Tissue Banks).


Prof. Raanan Berger

Raanan Berger, M.D, Ph.D, is the Director of the Sheba Medical Center cancer center, a senior Oncologist and Radiotherapist, and the head of the clinical research facility at the Institute of Oncology and Radiotherapy. Dr. Berger is leading the genitourinary oncology program, as well as running a basic and translational research lab studying molecular mechanisms in prostate and breast tumorigenesis

Dr. Berger holds a MD and PhD degrees from the Sackler Medical School at Tel Aviv University. He completed his clinical training in Medical Oncology and Radiotherapy at Sheba Medical Center and his postdoctoral fellowship at Dana Farber Cancer Institute at Harvard Medical School. During that time, Dr. Berger combined clinical work treating prostate cancer patients with Dr. Philip Kantoff with basic research in Dr. William C. Hahn’s lab. Dr. Berger has developed a novel prostate cancer model derived from primary human prostate epithelial cells with defined genetic elements. He is the co-author of 20 peer reviewed scientific articles.

Prof. Frederick F. Lang

Dr. Lang is Chair of Neurosurgery and Director of the Brain Tumor Center at The University of Texas MD Anderson Cancer Center. He also serves as co-leader of the institution’s Glioblastoma Moon Shot®. Dr. Lang holds the Beau Biden Chair for Brain Cancer Research.

Dr. Lang received his medical degree from Yale School of Medicine in 1988. He completed an internship in general surgery and a residency in neurosurgery at New York University Medical Center. In 1995, he joined MD Anderson as a fellow in neurosurgical oncology and became a member of the faculty in 1996.

Dr. Lang is a widely respected researcher and surgeon. He is internationally recognized as a pioneer in the surgical resection of deep-seated brain tumors, particularly tumors in the insula, and in the treatment of brain metastases. He is a physician scientist who is known for his innovative clinical trials evaluating novel therapies for brain tumors.

Dr. Lang is the principal investigator (PI) of the multidisciplinary Specialized Programs of Research Excellence (SPORE) in Brain Cancer. He is a National Institutes of Health-funded translational researcher who has published extensively on gene, viral and cellular therapies for brain tumors and is PI on multiple clinical trials that investigate these new approaches. His
groundbreaking work has provided immense promise to revolutionize the way we treat glioblastoma patients. He is currently working on strategies to improve the delivery of biological agents to tumors through the use of therapy-loaded cellular and nanoparticle carriers.

Dr. Lang recently received the Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research from MD Anderson Cancer Center. He is a fellow of the American Association for the Advancement of Science, a prestigious honor highlighting exceptional achievements. He was elected to the American Academy of Neurological Surgeons in 2009. His work has been recognized through many other awards and honors, including the Guha Award from the Society of Neuro-Oncology, and the Bittner Award from the Tumor Section of the American Association of Neurologic Surgeons (AANS) and the Congress of Neurological Surgeons (CNS).

Dr. Lang is a past president of the Society for Neuro-Oncology and past chair of the AANS/CNS Section on Tumors. He has served as an associate editor of Neurosurgery and on the editorial board of Neuro-Oncology and Translational Oncology. Dr. Lang’s internationally recognized work has been published widely in more than 200 peer-reviewed journals, almost two dozen book chapters and numerous other publications.

Dr. Mitchel S. Berger

Mitchel S. Berger M.D., F.A.C.S., F.A.A.N.S. is the Berthold and Belle N. Guggenhime Professorof the Department of Neurological Surgery at the University of California, San Francisco (UCSF).He also serves as Director of UCSF’s Brain Tumor Center. Dr. Berger is a pioneer of intraoperative brain mapping — a technique used to avoid functional areas of the brain during surgical resection of a tumor. His work has enabled surgeons to perform more extensive resection of tumor with less chance of producing sensorimotor or language deficit. Dr. Berger is a leader of translational research and is the Principal Investigator of the UCSF Brain Tumor Research Center’s Specialized Program of Research Excellence in neuro-oncology, funded by the National Cancer Institute. His specific research interests lie in identifying molecular markers related to the progression and prognosis of glial tumors, as well as the development of small-molecule therapeutic agents that can be administered directly to the brain via convection-enhanced drug delivery. During his distinguished career, Dr. Berger has served as President of the American Association of Neurological Surgeons (AANS), President of the Society of Neuro-Oncology, and President of the American Academy of Neurological Surgery. He has also been a director of the American Board of Neurological Surgery; a member of the Board of Directors of the American Association of Neurological Surgeons; and a member of the Blue Ribbon Panel for the National Cancer Moonshot Initiative.

Drug Delivery:

Dr. Noam Emanuel

Dr. Noam Emanuel currently serves as Chief Technology Officer at Mileutis, a biopharmaceutical company focused on developing peptide-based medical solutions for animal and human health. Before joining Mileutis, Dr. Emanuel co-founded PolyPid Ltd. and served as its Chief Scientific Officer. He played a significant role in the company’s development, serving as CEO during its first three years.

Dr. Emanuel was instrumental in advancing the company’s proprietary drug delivery technologies and is the inventor of Polypid’s PLEX technology. He led several clinical programs up to the Phase 3 study. One of his notable contributions includes developing D-PLEX100, a product designed to prevent surgical site infections by providing localized, prolonged antibiotic release directly at the surgical site. Additionally, Dr. Emanuel has been instrumental in inventing and advancing Polypid’s OncoPLEX program, an intratumoral cancer therapy that has shown promising results in preclinical studies for glioblastoma.

Dr. Emanuel’s qualifications and expertise are rooted in his academic background and extensive experience. He holds a PhD. in Biotechnology from the Hebrew University of Jerusalem and has been a part of the biotechnology industry for over 25 years. His specialization includes drug delivery systems and immunology.

Clinical Development:

Dr. Yafit Stark

Dr. Stark is a pioneer and expert in global clinical development strategy.
Dr. Stark was Vice President of Global Clinical Development at Teva Pharmaceutical Industries, Ltd. she joined Teva in 1987. From 1991 to 1994 she established the Innovative R&D Division of Teva USA and was responsible for the clinical development of Copaxone®. Throughout the years she continued  building the Global Clinical Infrastructures of Teva and was responsible for the Clinical Development of other Teva products. During her long term career in the industry, Dr. Stark was involved in building new clinical therapeutic areas such as Oncology and Biosmilars as well as advancing new technologies into clinical trials. Dr. Stark holds a Ph.D. in Pathology from the Sackler School of Medicine, Tel Aviv University, and a Post-Doctorate in Immuno-Histopathology from Tel Aviv University and the Weizmann Institute of Science.